Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22614731 | 0.98 | CYP2D6 (0.36) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL16868406 | 0.82 | ALDH1A1 (0.55) | CYP2D6CHRM2ADRA2BADRA2CCHRM3 | |
| SCHEMBL21753375 | 0.82 | SLC6A2 (0.46) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL9559796 | 0.82 | ALDH1A1 (0.55) | CYP2D6CHRM2ADRA2BADRA2CCHRM3 | |
| SCHEMBL28312772 | 0.81 | CA1 (0.52) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL3007585 | 0.81 | CES2 (0.48) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL22614733 | 0.79 | CES2 (0.47) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL15520812 | 0.78 | ACACB (0.42) | KMT2AALDH1A1LOXL2CYP4F2CYP4A11 | |
| SCHEMBL20440713 | 0.78 | CYP4F2 (0.40) | CYP2D6KMT2ACHRM2ADRA2BADRA2C | |
| SCHEMBL25523231 | 0.78 | DPP4 (0.43) | KMT2ADPP4CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| US-20230054132-A1 | DNA APTAMER-CYANINE COMPLEXES AS GENERIC COLORIMETRIC SENSORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-02-23 | — | — | US | claimed |
| US-11060095-B2 | Method for isolating cross-reactive aptamer and use thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-07-13 | — | — | US | claimed |
| US-20210102210-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-04-08 | — | — | US | claimed |
| US-10907162-B2 | Method for isolating cross-reactive aptamer and use thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-02-02 | — | — | US | claimed |
| US-20200172907-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2020-06-04 | — | — | US | claimed |
| US-10655132-B1 | Method for isolating cross-reactive aptamer and use thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2020-05-19 | — | — | US | claimed |
| US-20200131514-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2020-04-30 | — | — | US | claimed |
| US-9671415-B2 | Immunoassay for pyrrolidinophenones | RANDOX LABORATORIES LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| EP-3841085-B1 | NBOME TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20260086062-A1 | IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-2442110-B1 | Drug detection | RANDOX LAB LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
| US-20120094316-A1 | Drug Detection | NORTHERN BANK LIMITED (IE) | 2012-04-19 | — | — | US | disclosed |
| EP-2442110-A1 | Drug detection | Randox Laboratories Ltd. (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A4, SLC6A3, SIGMAR1 | CYP2D6 25/4885KMT2A 1138/4885CHRM2 402/4885 |
| US-20210102210-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | SELE, ADAR, CDA | CYP2D6 1084/4885KMT2A 2831/4885CHRM2 2745/4885 |
| US-11060095-B2 | Method for isolating cross-reactive aptamer and use thereof | SELE, ADAR, CDA | CYP2D6 1084/4885KMT2A 2831/4885CHRM2 2745/4885 |
| US-10655132-B1 | Method for isolating cross-reactive aptamer and use thereof | SELE, ADAR, CDA | CYP2D6 1005/4885KMT2A 2423/4885CHRM2 2664/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | CYP2D6 385/4885KMT2A 1312/4885CHRM2 679/4885 |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A3, SIGMAR1, SLC6A4 | CYP2D6 29/4885KMT2A 1014/4885CHRM2 306/4885 |
| US-20120094316-A1 | Drug Detection | KIT, CYP3A43, CYP3A5 | CYP2D6 13/4885KMT2A 1155/4885CHRM2 156/4885 |
| US-10907162-B2 | Method for isolating cross-reactive aptamer and use thereof | SELE, ADAR, CDA | CYP2D6 980/4885KMT2A 2522/4885CHRM2 2704/4885 |
| US-20260086062-A1 | IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS | EBPL, ADA, XBP1 | CYP2D6 2181/4885KMT2A 1012/4885CHRM2 1821/4885 |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SIGMAR1, OPRK1, SLC6A2 | CYP2D6 26/4885KMT2A 452/4885CHRM2 393/4885 |
| US-20200172907-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | SELE, ADAR, CDA | CYP2D6 1005/4885KMT2A 2423/4885CHRM2 2664/4885 |
| US-20200131514-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | SELE, ADAR, CDA | CYP2D6 1005/4885KMT2A 2423/4885CHRM2 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.